NKTR-105

Market information
NKTR-105 is in a Phase 1 clinical trial in patients with certain types of solid tumors including hormone-refractory prostate cancer. Docetaxel is the only chemotherapeutic agent approved for use in five different cancer indications. It also could be explored as a therapy for breast, non-small cell lung, gastric, head and neck cancers. Each year, an estimated 3 million patients worldwide have been diagnosed with one of these types of cancer.

NKTR-105 Preclinical Data and Product Profile
NKTR-105 is a novel form of the anti-mitotic agent, docetaxel, and was designed using Nektar's advanced polymer conjugate technology. Nektar's pro-drug technology approach applied to docetaxel is expected to improve the pharmacokinetic profile of the drug, resulting in prolonged exposure of the tumor to docetaxel and an improved time-concentration profile. Additionally, the application of Nektar advanced polymer chemistry is expected to enable higher therapeutic concentrations of the drug to be achieved and sustained over a longer period with a lower dose than the parent molecule, so as to potentially yield an enhanced therapeutic effect and improved tolerability.

Events related to this product

View our Scientific & Medical event calendar »